| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1225-1233.)
© 2007 American Heart Association, Inc.
Heart Failure |
From the Division of Cardiology, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md (S.W., M.S., J.M.M., S.U.H., M.C.P.H.); Department of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore (A.M.R., D.H.S.); Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, Baltimore, Md (A.M.R.); and Division of Cardiology, Walter Reed Army Medical Center, Washington, DC (E.E.).
Correspondence to Mark C.P. Haigney, MD, Division of Cardiology, Department of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814. E-mail MCPH{at}aol.com
Received July 25, 2006; accepted December 29, 2006.
| Abstract |
|---|
|
|
|---|
Methods and Results We investigated ß-adrenergic receptor and muscarinic receptor regulation of the cardiac NCX in control and heart failure (HF) conditions in atrially paced pigs. NCX current in myocytes from control swine hearts was significantly increased by isoproterenol, and this response was reversed by concurrent muscarinic receptor stimulation with the addition of carbachol, demonstrating "accentuated antagonism." Okadaic acid eliminated the inhibitory effect of carbachol on isoproterenol-stimulated NCX current, indicating that muscarinic receptor regulation operates via protein phosphataseinduced dephosphorylation. However, in myocytes from atrially paced tachycardia-induced HF pigs, the NCX current was significantly larger at baseline but less responsive to isoproterenol compared with controls, whereas carbachol failed to inhibit isoproterenol-stimulated NCX current, and 8-Br-cGMP did not restore muscarinic responsiveness. Protein phosphatase type 1 dialysis significantly reduced NCX current in failing but not control cells, consistent with NCX hyperphosphorylation in HF. Protein phosphatase type 1 levels associated with NCX were significantly depressed in HF pigs compared with control, and total phosphatase activity associated with NCX was significantly decreased.
Conclusions We conclude that the NCX is autonomically modulated, but HF reduces the level and activity of associated phosphatases; defective dephosphorylation then "locks" the exchanger in a highly active state.
Key Words: calcium electrophysiology heart failure receptors, adrenergic, beta sodium
| Introduction |
|---|
|
|
|---|
Clinical Perspective p 1233
Cardiac output is controlled on a beat-to-beat basis by the interaction of the sympathetic and parasympathetic nervous systems. Cardiac sympathetic stimulation activates the ß-adrenergic receptor (ß-AR), whereas parasympathetic stimulation acts on cardiac muscarinic receptor (M-2) systems. These signaling systems interact to regulate cardiac contractility and rate by modulating critical effector proteins7 via "accentuated antagonism,"8 a phenomenon in which the effect of sympathetic stimulation is rapidly reversed by parasympathetic stimulation despite continued application of the initial stimulus. Accentuated antagonism allows rapid increases in cardiac output in response to physiological challenge while preventing toxicity from excess adrenergic tone.9 In HF both ß-AR and M-2 cardiac responsiveness are depressed, contributing to lost cardiac reserve, increased arrhythmic susceptibility,10 and death. However, the underlying cellular mechanism of these phenomena is far from clear. Some studies have attributed this loss of autonomic responsiveness to the desensitization of ß-AR receptors and/or downregulation of signal transduction in HF.11,12 However, recent work suggests that the L-type Ca2+ channel and ryanodine receptor are tonically phosphorylated ("hyperphosphorylated") at baseline in failing human myocytes,1316 which could contribute to depressed ß-AR responsiveness in cardiac function in HF. Some investigators, but not all, have suggested that the NCX is regulated by ß-AR1719 and M-2 systems.20 Schulze et al21 reported that the NCX in heart is found in a macromolecular complex containing protein kinase A (PKA), protein kinase C, and the protein phosphatases PP1 and PP2a. We recently reported that the NCX current in HF was increased in the basal state,22 manifesting blunted ß-AR regulation, and that these alterations are due to NCX hyperphosphorylation in HF.23
The effect of hyperphosphorylation on the muscarinic modulation of the affected proteins has not been investigated previously. In the present study, we investigated ß-AR and M-2 regulation of the NCX in both control and HF states using a pacing-induced failing pig model. Our new model is similar to that reported previously except that the present study was performed in atrially (as opposed to ventricularly) paced animals. Rapid atrial pacing results in ventricular dilatation, neurohormonal activation, and loss of ß-AR responsiveness similar to other HF models.24,25 The change in protocol was introduced for the following reasons: ventricular pacing bypasses the His-Purkinje conduction system and alters the normal pattern of ventricular depolarization, whereas atrial pacing does not (in the absence of conduction system disease).26 Altered ventricular depolarization has numerous effects on cellular protein expression, including the distribution of gap junctions27 and NCX protein density (David Rosenbaum, MD, PhD, personal communication, June 6, 2005). Ventricular pacing per se may introduce phenotypic changes in ventricular myocytes that confound our ability to assess the effect of HF. Additionally, ventricular pacing causes significant changes in ventricular repolarization, preventing a meaningful assessment of the impact of HF on the surface ECG and T wave. Using our refined HF model, we found that in HF the NCX was highly active and displayed markedly depressed ß-AR and M-2 responsiveness. The common pathway of these alterations is downregulation of protein phosphatase expression and activity associated with the NCX, resulting in defective NCX dephosphorylation in HF.
| Methods |
|---|
|
|
|---|
Cardiomyocyte Isolation and Culture
On development of severe left ventricular dysfunction, animals were euthanized with pentobarbital sodium. The hearts were harvested by left lateral thoracotomy and immersed in ice-cold saline. The region of ventricle perfused by the left anterior descending coronary artery was excised, cannulated, and perfused at 15 mL/min for 10 minutes with nominally Ca2+-free modified Tyrodes solution (in mmol/L: NaCl 138, KCl 4, MgCl2 1, NaH2PO4 0.33, glucose 10, and HEPES 10 [pH 7.3 with NaOH] at 37°C and oxygenated with 100% O2). Perfusion was continued with the same solution but containing 0.24% (wt/vol) collagenase type I (Sigma, St Louis, Mo) and 0.028% protease XIV (Sigma) for 12 minutes and then for 10 minutes with washout solution with 0.1 mmol/L CaCl2 and 0.02% albumin. Sections of well-digested ventricular tissue from the midmyocardial layer of the ventricle were excised, and cells were mechanically dissociated and resuspended in buffers of gradually increasing [Ca2+]. To remove dead myocytes and residual contaminating cell types, the myocyte suspension was centrifuged through a discontinuous Percoll gradient, usually resulting in >90% rod-shaped cells. To allow the myocytes to recover from enzymatic digestion, the cells were cultured overnight at 37°C in serum-free medium 199, supplemented with 5 mmol/L carnitine, 5 mmol/L creatine, 5 mmol/L taurine, 100 µg/mL penicillin, 100 units/mL streptomycin, and 0.25 µg/mL amphotericin. We have found that this approach increases the rate of successful giga-seal formation without significantly altering phenotype with regard to NCX function and ß-AR regulation.
Electrophysiology
Whole-cell recordings were obtained at 37°C with the use of standard patch-clamp techniques. Membrane current was assessed by use of an Axopatch-100A amplifier and a 1/100 CV-3 head stage (Axon Instruments). Experimental control, data acquisition, and data analysis were accomplished with the use of the software package Pclamp 8.0 with the Digidata 1200 acquisition system (Axon Instruments). Patch pipettes were pulled from thin-walled glass capillary tubes and heat polished. The electrode resistance ranged from 1 to 2 M
. The external solution contained the following (in mmol/L): NaCl 145, MgCl2 1, HEPES 5, CaCl2 2, CsCl 5, and glucose 10 (pH 7.4, adjusted with NaOH). Ouabain (0.02 mmol/L) and nifedipine (0.01 mmol/L) were added to the solution. The full scale of ß-adrenergic stimulation was achieved by addition of isoproterenol (2 µmol/L). The internal solution contained the following (in mmol/L): CsCl 65, NaCl 20, Na2ATP 5, CaCl2 6, MgCl2 4, HEPES 10, tetraethyl ammonium chloride 20, EGTA 21, and ryanodine 0.05 (pH 7.2, adjusted with CsOH). In a separate set of experiments, protein phosphatase type 1 (PP1) (10 U/mL) was added to the internal solution to explore the role of tonic phosphorylation of the NCX in the increased basal INCX in HF. Membrane currents were elicited with the use of standard voltage ramp protocol. From a holding potential of 40 mV, a 100-ms step depolarization to +80 mV was followed by a descending voltage ramp (from +80 mV to 120 mV at 100 mV/s). The protocol was applied every 10 seconds. INCX was measured as the Ni-sensitive current. Ni2+ (5 mmol/L) was added to define the fraction of current that derives from NCX (the difference between total current and post-Ni2+ current). Membrane capacitance was read directly from the membrane test of Pclamp 8.0 before compensating for series resistance and membrane capacitance.
Identity of the Bidirectional, Ni-Sensitive Current
To test whether our recordings were significantly contaminated by the cAMP-dependent Cl current (CFTR) or the Ca-activated Cl current, we applied niflumic acid (100 µmol/L, Ca-activated Cl blocker) and glibenclamide (100 µmol/L, CFTR blocker). In separate experiments, we tested whether reducing extracellular Cl (from 145 to 8 mmol/L) and whether removing extracellular Ca2+ would rapidly and reversibly suppress the isoproterenol-stimulated current.
Detection and Quantification of the Phosphatases
The total protein from ventricles of normal and failure pig hearts was extracted, and the Western blots were prepared as previously described.21,23 The NCX antigen complex NCX antibody/Protein A Sepharose was obtained and prepared for Western blots and then immunoblotted with PP2a antibody (BD Biosciences, San Jose, Calif). After the PP2a in the immunoprecipitated NCX complex was identified, the same nitrocellulose membrane was reprobed with NCX antibody after the membrane was stripped of antibodies from the previous experiment. Similarly, another Western blot membrane was immunoblotted with PP1 antibody (Upstate Cell Signaling Solutions, Charlottesville, Va) and then with NCX antibody. With the use of ECL systems (GE Healthcare, Lake Placid, NY), the results were recorded on Biomax Kodak film. The images in the negative films were scanned and analyzed with the use of ImageQuant software (GE Healthcare Systems). Additionally, the ß-1, ß-2, and muscarinic receptor proteins were immunoprecipitated with the use of the appropriate antibody and quantified by Western blot.
Phosphatase Assay
To analyze the total activity of the phosphatases in heart extract and the phosphatases associated with the NCX complex, para-nitrophenyl phosphate was used as a substrate, and the measurements were made following the protocol of the Phosphatase Assay Kit (Upstate Cell Signaling Solutions, Lake Placid, NY). Phosphatase activity for the normal and failure heart extracts (each containing 35 µg of total protein) was estimated. The phosphatase activity associated with NCX was determined for proteins binding to NCX. The NCX macromolecular complex was obtained by incubating 1.2 µL of antibody serum (
11-13) with the concentrated heart extract of 350 µL overnight. The NCX complex was washed thoroughly in 800 mL of the wash buffer.28 Enzyme activity was measured for 10 minutes at 37°C. The absorbance was measured at 405 nm. The phosphatase activity in normal heart was considered to be 100% and was compared with change in HF activity.
Protein Phosphatase Activity of PP1 and PP2a
The phosphatase activity of normal and failure heart extracts was determined with the use of the specific phosphopeptide (KRpTIRR) as a substrate for PP1 and PP2A phosphatase enzymes. The phosphate released was visualized with the use of malachite green following the manufacturers instructions (Serine/Threonine Phosphatase Assay Kit, Upstate Cell Signaling Solutions, Charlottesville, Va). The solutions were incubated for 20 minutes at room temperature, and color development was measured at 620 nm. The amount of enzyme activity was compared with those measured by the para-nitrophenyl phosphate method.
Statistical Analysis
Data are presented as mean±SEM. Continuous variables were compared by paired or unpaired t test. A probability value of <0.05 was regarded as a statistically significant finding.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
|
Glibenclamide and niflumic acid, blockers of the CFTR and Ca-activated Cl currents, respectively, had no effect on the magnitude of the isoproterenol-stimulated, Ni-sensitive current whether given together (Figure 1B) or separately (not shown). In separate experiments, we found that reducing extracellular chloride (from 145 to 8 mmol/L) had no effect on the magnitude of the isoproterenol-stimulated current (Figure 1C), whereas removing Ca2+ rapidly and reversibly suppressed the isoproterenol-stimulated current (Figure 1D). Taken together, these data exclude significant contamination by either the CFTR or Ca-activated chloride current and support the identity of the current as NCX.
Blunted ß-AR and M-2 Regulation of the NCX Current in HF
Recent evidence suggests that ß-AR stimulation increases NCX activity in mammalian myocytes and that M-2 stimulation can modulate this effect.1720 Figure 2A1 shows a representative tracing of INCX from control myocytes in basal conditions, in the presence of the ß-AR agonist isoproterenol (2 µmol/L/L), and in the presence of isoproterenol plus the M-2 agonist carbachol (5 µmol/L). Isoproterenol markedly increased outward and inward INCX in control myocytes, and carbachol significantly inhibited the isoproterenol-stimulated effect. The mean population data of peak outward current density (at +70 mV) reveals that isoproterenol increased INCX
300% in controls, whereas carbachol almost completely reversed it (P<0.01; Figure 2A2). However, in failing myocytes basal INCX was significantly increased compared with control myocytes, whereas isoproterenol manifested blunted stimulation, increasing the peak INCX to a significantly lesser extent (Figure 2B2). The application of the M-2 agonist carbachol did not result in a significant inhibitory effect on isoproterenol-stimulated INCX in HF cells (Figure 2B2). This is the first direct evidence of blunted M-2 regulation of the NCX current in HF. Our previous study in a ventricularly paced HF model demonstrated that increased basal INCX and reduced ß-AR responsiveness are due to hyperphosphorylation of NCX in HF, but the mechanism of hyperphosphorylation and the interaction with the muscarinic system were not elucidated. Possible explanations for the failure of muscarinic modulation in HF include a decrease in M-2 receptor number, downregulated signal transduction, and/or altered protein phosphorylation state. These alternatives are investigated in the following experiments.
|
Altered Receptor Number and Downregulated Signal Transduction Are Excluded for Explaining Blunted ß-AR and M-2 Regulation of NCX Current in HF
We found no evidence of a reduction in either muscarinic or ß-adrenergic receptor protein expression in HF, suggesting that receptor number was not changed drastically in our model and pointing to a defect in signal transduction (see online-only Data Supplement). Stimulation of the cardiac muscarinic receptor (mainly M-2) is thought to activate soluble guanylyl cyclase, leading to an increase in intracellular cyclic GMP (cGMP). This increase in cytosolic cGMP could either activate cGMP-dependent protein kinase G (PKG) to phosphorylate effectors or activate a protein phosphatase to dephosphorylate PKA-induced phosphorylation.
To identify the altered steps resulting in blunted ß-AR and M-2 regulation of INCX in HF, we exposed failing cells to 8-Br-cAMP and 8-Br-cGMP to directly stimulate PKA and PKG. In control myocytes, cAMP (1 mmol/L) significantly increased INCX in a manner similar to that of isoproterenol, whereas cGMP significantly reversed this effect; cGMP also reversed the effect of isoproterenol (Figure 3). In failing myocytes, however, both cGMP effects were blunted, suggesting that the impaired ß-AR and M-2 regulation is not due to reduced receptor number or uncoupling of the ß-AR and M-2 signaling pathways. Rather, the defect must be downstream from the generation of cAMP and cGMP.
|
Muscarinic System Antagonizes ß-AR Stimulation via Protein Phosphatase
Figure 4A shows that okadaic acid (1 µmol/L) significantly reversed the carbachol inhibition of isoproterenol-stimulated NCX current in control myocytes. This result suggests that a protein phosphatase is a crucial component for M-2 regulation of NCX in myocytes and argues for dephosphorylation as opposed to phosphorylation as a mechanism for M-2 modulation of the NCX. Furthermore, if a protein phosphatase is the mediator of M-2 modulation in the control state, it follows that infusion of exogenous protein phosphatase enzyme should reverse isoproterenol stimulation in HF in a manner similar to that of carbachol in the controls. In a separate experiment, dialysis of PP1 (10 U/mL) through the intracellular solution significantly inhibited INCX in basal and isoproterenol-stimulated conditions in failing myocytes but had no significant effect on basal current in control myocytes (Figure 4B). These data suggest that M-2 stimulation inhibits isoproterenol-stimulated INCX through activation of a protein phosphatase and that excessive protein phosphorylation in HF results in both increased basal activity and decreased ß-AR responsiveness. A unifying hypothesis explaining these phenomena, as well as the failure of the NCX to respond to M-2 stimulation in HF, would be that the protein phosphatase associated with the NCX is significantly downregulated or inhibited in HF. To test this hypothesis, we measured protein phosphatase levels and activity in protein precipitated with the NCX complex.
|
Protein Phosphatases Associated With NCX in HF
To test whether the protein phosphatases associated with the NCX are decreased in HF, we examined PP1- and PP2a-associated NCX with a specific antibody directed against PP1 and PP2a in NCX proteins immunoprecipitated by NCX antibody. The NCX proteins were immunoprecipitated by NCX antibody from control and failing heart tissues. The proteins in the NCX complex were separated with the use of PAGE and transferred to nitrocellulose membranes. These membranes were immunoblotted with PP2a antibodies, and the same blot was reprobed with NCX antibody after the membrane was stripped of antibodies from a previous experiment. Figure 5A is a representative Western blot of PP1 and PP2a in control and failing heart samples, showing that PP1 protein is significantly reduced in HF. Surprisingly, PP2a expression appears significantly increased in failing heart muscle compared with control in absolute terms (Figure 5B; P<0.05). However, the total amount of NCX protein was increased in failing hearts by
40% (Figure 5B; P<0.05). After normalization for the amount of NCX protein from control and failing hearts, group analysis confirmed that the mean amount of PP1 in failing hearts was 33% that in control hearts (P<0.01), but PP2a levels were not altered with respect to NCX. To test whether this relative shift in protein expression would alter phosphatase activity, we assessed protein phosphatase activity associated with the NCX and in bulk myocardium with para-nitrophenyl phosphate and malachite green methods. Protein phosphatase activity associated with the NCX was significantly depressed in failing heart compared with control, but no significant difference existed between protein phosphatase activity in bulk myocardium between failure and control states (Figure 6). These results provide direct evidence that protein phosphatase activity associated with the NCX is downregulated in HF.
|
|
| Discussion |
|---|
|
|
|---|
Modulation of the NCX by the ß-AR and Muscarinic Systems
Controversy exists regarding whether the cardiac NCX is modulated by PKA.29,30 The cAMP-dependent Cl current (CFTR) and the Ca-activated Cl current are reported to be Ni2+ sensitive and have reversal potentials similar to those of NCX.31 Lin et al32 have suggested that these conductances could contaminate our recordings of NCX, especially during stimulation of the ß-AR, causing an overestimation of the effect of isoproterenol on the NCX. In the present study, we found no effect of significantly reducing extracellular chloride on the bidirectional, Ni2+-sensitive current in pig ventricular myocytes. Additionally, we found that the current was Ca2+ dependent, which is consistent with the NCX but not CFTR. Our result is consistent with other reports that although the CFTR conductance is highly represented in small animals, it is nearly or completely absent in large animals such as dogs or humans.33 Further underscoring the significance of interspecies differences, Ginsburg and Bers34 found no evidence of isoproterenol stimulation of NCX in meticulously controlled experiments in nonfailing rabbits. Although we have no experience with this model, one wonders whether differences in phosphatase activity may account for differences in response to isoproterenol; in such a case, an alternative approach using a phosphatase inhibitor might have yielded evidence of NCX augmentation. Our findings, furthermore, are consistent with those of other groups who found significant increases in NCX current after stimulation with isoproterenol.17,18,20 The exchanger has been reported to be associated with the regulatory R-1 complex comprising PKA, AKAP, PP1, protein kinase C, and PP2a,21 an important piece of evidence suggesting autonomic regulation. Nevertheless, the PKA phosphorylation site on the exchanger has not been identified. The rat cardiac NCX1 sequence presents 5 probable sites, of which 3 are intracellular (threonine at 74 and 618; serine at 389). Methodological differences in the assessment of NCX activity may also contribute to conflicting results. Caffeine superfusion during voltage clamp is a time-honored alternative method of detecting and quantifying the exchange current, but for purposes of studying changes induced by phosphorylation of the exchanger, the ramp method may be superior because it should be less sensitive to changes in sarco/endoplasmic reticular Ca2+-ATPase function and sarcoplasmic reticular calcium load.
Further evidence that the NCX is regulated by the autonomic nervous system in a manner that is relevant to human disease is accumulating. Although stimulation of the M-2 receptor by carbachol in the absence of preceding ß-AR stimulation has been shown to induce an indirect increase in the NCX current via subsarcolemmal Na+ gain,35 the present study confirms the observations of Zhang et al20 that NCX activity is strongly depressed by muscarinic agonists administered during ß-AR stimulation, but the mechanism of signal transduction was not previously elucidated. Investigating the L-type Ca channel, Jiang et al36 reported that M-2 modulates ß-AR stimulation via PKG-induced L-type channel phosphorylation, whereas Shen and Pappano37 have suggested that the primary response of cGMP is to activate protein phosphatases to dephosphorylate PKA-induced phosphorylation. To examine these putative mechanisms, we reasoned that if the muscarinic effect is modulated by phosphorylation of a separate site on the NCX in the presence of isoproterenol, then application of a nonspecific protein phosphatase inhibitor, ie, okadaic acid, should increase (or at least not inhibit) muscarinic modulation of the current by allowing further accumulation of phosphorylation. Alternatively, if M-2 stimulation results in activation of an NCX-associated protein phosphatase, inhibition of that phosphatase by okadaic acid should reverse the effect of M-2 stimulation and restore the current. We found that okadaic acid indeed reversed the carbachol effect, consistent with activation of a phosphatase as the mechanism of muscarinic modulation of the NCX. Finally, Katanosaka et al38 have reported that the C-terminus of the Aß of calcineurin, a phosphatase mechanistically implicated in cardiac hypertrophy, binds to the cytoplasmic loop of the cardiac NCX in hamsters. Prolonged phenylephrine exposure, which would stimulate the
-adrenergic system and act as a model of hypertension, resulted in inhibition of Na+o-dependent Ca2+ efflux from isolated myocytes in a manner that was prevented by inhibition by calcineurin. This is consistent with differential phosphatase modulation by distinct pathological signaling mechanisms.
Blunted ß-AR and M-2 Regulation in HF
Recent studies have suggested that elevated tonic phosphorylation (hyperphosphorylation) of calcium handling proteins such as the L-type Ca channel and the ryanodine receptor might contribute to increased basal Ca2+ permeability and reduced responsiveness to ß-AR stimulation. In our previous study, we also found that the NCX is hyperphosphorylated in HF, suggesting that downregulated protein phosphatase might be the underlying mechanism. In the present study, we have demonstrated reduced PP1 protein and protein phosphatase activity associated with the NCX, providing a mechanism for NCX hyperphosphorylation in HF. The present study differs somewhat from our previous work in that these animals were atrially paced into HF. This change should avoid artifactual changes in myocyte phenotype due to abnormal depolarization; however, the magnitude of the increase in the basal current due to HF appears to be 25% less than we found previously despite similar increases in NCX expression. The most likely explanation is that rapid ventricular pacing induces a more severe HF phenotype because of the introduction of intraventricular and atrioventricular dyssynchrony that would not be appreciated by echocardiograms performed in sinus rhythm.
In the present study, we found that the M-2 receptor agonist carbachol loses its ability to inhibit ß-AR stimulation on the NCX in HF. In contrast to the decreased numbers of ß-AR receptors found in HF, the number of M-2 receptors is either unchanged or increased in HF.39 We found that application of cGMP fails to recover M-2 inhibition of ß-AR signaling, confirming that the defect of muscarinic regulation is not at the M-2 receptor and/or Gi protein and must be downstream of cGMP. However, dialysis with PP1 significantly depressed both NCX current in basal conditions and after isoproterenol stimulation in HF. Furthermore, the protein phosphatase inhibitor okadaic acid eliminates carbachol inhibition of isoproterenol-stimulated INCX, indicating that M-2 regulation of the NCX is dependent on protein phosphatase activity. On the basis of these findings, we suggest that both ß-AR and M-2 dysfunction in HF are due to downregulation of protein phosphatase, principally PP1.
Downregulated Protein Phosphatase Associated With NCX in HF
The effect of HF on protein phosphatase expression and activity is clearly complex. Neumann et al40 have reported that cardiac PP1 protein and mRNA levels were increased in HF, resulting in decreased phospholamban phosphorylation and depressed sarcoplasmic reticulumATPase function, whereas other groups have found decreased local protein phosphatase expression. Marx et al14 found that the protein levels of both PP1 and PP2a associated with ryanodine receptor were reduced in HF. In the present study, we found that the NCX associates with protein phosphatases in a macromolecular complex in pig hearts, similar to findings in the rat. In contrast to the results of Marx et al (with respect to the ryanodine receptor), however, we found that PP1 expression is decreased, whereas PP2a associated with the NCX is unchanged in HF. Despite this shift in phosphatase profile associated with the complex, we found that total protein phosphatase activity associated with NCX is significantly depressed in HF compared with control (whereas total myocardial activity is unchanged). These results suggest that PP1 might play a principal role in NCX dephosphorylation in the control state, whereas PP2a is predominant in HF. Although it is generally believed that PP1 and PP2a have similar activity in terms of dephosphorylation of serine/threonine sites, the structure, activity, and regulation of these isoforms are distinct.41,42 PP1 activity is modulated by the inhibitor protein I-1, which is itself activated by PKA phosphorylation. PP2a can dephosphorylate I-1,43 but little is known about the regulation of PP2a itself. A recent report has suggested that the enzyme is inhibited by elevated [Ca2+]I,44 whereas overexpression of PP2a has been shown to result in reduce cardiac contractility.45 The present study suggests that PP2a activity is not modulated by muscarinic stimulation, resulting in failure of dephosphorylation of the NCX in response to M-2 stimulation. The effect of this shift in phosphatase isoform expression on NCX regulation and the HF phenotype merits further investigation.
Conclusions
Fifty percent of the deaths in patients with HF are sudden and presumably arrhythmic. Increased NCX activity in HF is likely to enhance depolarizing current, particularly when associated with spontaneous calcium release from the sarcoplasmic reticulum, which could result in afterdepolarizations triggering fatal ventricular arrhythmia. Furthermore, excess NCX activity has been tied to depression of the systolic calcium transient in HF, linking the NCX to mechanical pump dysfunction as well. The present study shows that in HF, the NCX is "locked" in a relatively high activity state and insensitive to both ß-AR and M-2 regulation, which could reduce cardiac contractile reserve and increase susceptibility to arrhythmia. The common pathway of these alterations is downregulation of associated protein phosphatase activity, resulting in defective NCX dephosphorylation in HF. Dephosphorylation of the NCX represents a possible therapeutic target for reducing arrhythmia and pump dysfunction in HF.
| Acknowledgments |
|---|
The present study was supported in part by grants from the Department of Defense (CO83OD to Dr Haigney; C083QF to Dr McCurley), the National Institutes of Health (HL62521 to Dr Schulze), the National Institutes of Aging (AG-020823 to Dr Ruknudin), and the American Heart Association (0265463U to Dr Wei; 9730173N to Dr Ruknudin).
Disclosures
None.
| References |
|---|
|
|
|---|
2. Hasenfuss G, Schillinger W, Lehnart SE. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation. 1999; 99: 641648.
3. ORourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, Marban E. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res. 1999; 84: 562570.
4. Pogwizd SM, Qi M, Yuan W, Samarel AM, Bers DM. Upregulation of Na+/Ca2+ exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res. 1999; 85: 10091019.
5. Hobai IA, Maack C, ORourke B. Partial inhibition of sodium/calcium exchange restores cellular calcium handling in canine heart failure. Circ Res. 2004; 95: 292299.
6. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res. 2001; 88: 11591167.
7. Takasago T, Imagawa T, Shigekawa M. Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J Biochem. 1989; 106: 872877.
8. Levy MN. Sympathetic-parasympathetic interactions in the heart. Circ Res. 1971; 29: 437.
9. Vanoli E, Schwartz PJ. Sympathetic-parasympathetic interaction and sudden death. Basic Res Cardiol. 1990; 85: 305321.[Medline] [Order article via Infotrieve]
10. Schwartz PJ. The autonomic nervous system and sudden death. Eur Heart J. 1998; 19: F72F80.[Medline] [Order article via Infotrieve]
11. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982; 307: 205211.[Abstract]
12. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311: 819823.[Abstract]
13. Schroder F, Handrock R, Beuckelmann DJ, Hirt S, Hullin R, Priebe L, Schwinger RH, Weil J, Herzig S. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation. 1998; 98: 969976.
14. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000; 101: 365376.[CrossRef][Medline] [Order article via Infotrieve]
15. Chen X, Piacentino V 3rd, Furukawa S, Goldman B, Margulies KB, Houser SR. L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res. 2002; 91: 517524.
16. Kamp TJ, He JQ. L-type Ca2+ channels gaining respect in heart failure. Circ Res. 2002; 91: 451453.
17. Perchenet L, Hinde AK, Patel KC, Hancox JC, Levi AJ. Stimulation of Na/Ca exchange by the beta-adrenergic/protein kinase A pathway in guinea-pig ventricular myocytes at 37 degrees C. Pflugers Arch. 2000; 439: 822828.[CrossRef][Medline] [Order article via Infotrieve]
18. Ruknudin A, He S, Lederer WJ, Schulze DH. Functional differences between cardiac and renal isoforms of the rat Na+-Ca2+ exchanger NCX expressed in Xenopus oocytes. J Physiol. 2000; 529: 599610.
19. Wei SK, Hanlon SU, Haigney MC. Beta-adrenergic stimulation of pig myocytes with decreased cytosolic free magnesium prolongs the action potential and enhances triggered activity. J Cardiovasc Electrophysiol. 2002; 13: 587592.[CrossRef][Medline] [Order article via Infotrieve]
20. Zhang YH, Hinde AK, Hancox JC. Anti-adrenergic effect of adenosine on Na(+)-Ca(2+) exchange current recorded from guinea-pig ventricular myocytes. Cell Calcium. 2001; 29: 347358.[CrossRef][Medline] [Order article via Infotrieve]
21. Schulze DH, Muqhal M, Lederer WJ, Ruknudin AM. Sodium/calcium exchanger (NCX) macromolecular complex. J Biol Chem. 2003; 278: 2884928855.
22. Wei SK, Hanlon SU, Haigney MCP. Decreased
-adrenergic responsiveness of Na/Ca exchange current in failing pig myocytes. Ann NY Acad Sci. 2002; 976: 472476.[Medline]
[Order article via Infotrieve]
23. Wei SK, Ruknudin A, Hanlon SU, McCurley JM, Schulze DH, Haigney MC. Protein kinase A hyperphosphorylation increases basal current but decreases beta-adrenergic responsiveness of the sarcolemmal Na+-Ca2+ exchanger in failing pig myocytes. Circ Res. 2003; 92: 897903.
24. Tanaka R, Fulbright BM, Mukherjee R, Burchell SA, Zile MR, Spinale FG. The cellular basis for the blunted response to
-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol. 1993; 25: 12151233.[CrossRef][Medline]
[Order article via Infotrieve]
25. Spinale FG, Fulbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, Zile MR. Relationship between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res. 1992; 71: 174187.
26. Patberg KW, Rosen MR. Molecular determinants of cardiac memory and their regulation. J Mol Cell Cardiol. 2004; 36: 195204.[CrossRef][Medline] [Order article via Infotrieve]
27. Shvilkin A, Danilo P, Wang J, Burkhoff D, Anyukhovsky EP, Sosunov EA, Hara M, Rosen MR. Evolution and resolution of long-term cardiac memory. Circulation. 1998; 97: 18101817.
28. Ivanina T, Perets T, Thornhill WB, Levin G, Dascal N, Lotan I. Phosphorylation by protein kinase A of RCK1 K+ channels expressed in Xenopus oocytes. Biochemistry. 1994; 33: 87868792.[CrossRef][Medline] [Order article via Infotrieve]
29. Condrescu M, Gardner JP, Chernaya G, Aceto JF, Kroupis C, Reeves JP. ATP-dependent regulation of sodium-calcium exchange in Chinese hamster ovary cells transfected with the bovine cardiac sodium-calcium exchanger. J Biol Chem. 1995; 270: 91379146.
30. Collins A, Somlyo AV, Hilgemann DW. The giant cardiac membrane patch method: stimulation of outward Na(+)-Ca2+ exchange current by MgATP. J Physiol. 1992; 454: 2757.
31. Xue L, Jo H, Matsuoka S. Ni2+ inhibits both Na-Ca exchange and cAMP-dependent Cl currents in guinea-pig ventricular cells. Biophys J. 2003; 86: 613a. Abstract.
32. Lin X, Jo H, Sakakibara Y, Tambara K, Kim B, Komeda M, Matsuoka S. Beta-adrenergic stimulation does not activate Na+/Ca2+ exchange current in guinea pig, mouse, and rat ventricular myocytes. Am J Physiol. 2006; 290: C601C608.[CrossRef]
33. Du XY, Finley J, Sorota S. Paucity of CFTR current but modest CFTR immunoreactivity in non-diseased human ventricle. Pflugers Arch. 2000; 440: 6167.[Medline] [Order article via Infotrieve]
34. Ginsburg KS, Bers DM. Isoproterenol does not enhance Ca-dependent Na/Ca exchange current in intact rabbit ventricular myocytes. J Mol Cell Cardiol. 2005; 39: 972981.[CrossRef][Medline] [Order article via Infotrieve]
35. Saeki T, Shen JB, Pappano AJ. Carbachol promotes Na+ entry and augments Na/Ca exchange current in guinea pig ventricular myocytes. Am J Physiol. 1997; 273: H1984H1993.[Medline] [Order article via Infotrieve]
36. Jiang LH, Gawler DJ, Hodson N, Milligan CJ, Pearson HA, Porter V, Wray D. Regulation of cloned cardiac L-type calcium channels by cGMP-dependent protein kinase. J Biol Chem. 2000; 275: 61356143.
37. Shen JB, Pappano AJ. On the role of phosphatase in regulation of cardiac L-type calcium current by cyclic GMP. J Pharmacol Exp Ther. 2002; 301: 501506.
38. Katanosaka Y, Iwata Y, Kobayashi Y, Shibisaki F, Wakabayashi S, Shigekawa M. Calcineurin inhibits Na+/Ca2+ exchange in phenylephrine-treated hypertrophic cardiomyocytes. J Biol Chem. 2005; 280: 57645772.
39. Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study. Circulation. 1997; 96: 34163422.
40. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol. 1997; 29: 265272.[CrossRef][Medline] [Order article via Infotrieve]
41. Luss H, Klein-Wiele O, Boknik P, Herzig S, Knapp J, Linck B, Muller FU, Scheld HH, Schmid C, Schmitz W, Neumann J. Regional expression of protein phosphatase type 1 and 2A catalytic subunit isoforms in the human heart. J Mol Cell Cardiol. 2000; 32: 23492359.[CrossRef][Medline] [Order article via Infotrieve]
42. duBell WH, Lederer WJ, Rogers TB. Dynamic modulation of excitation-contraction coupling by protein phosphatases in rat ventricular myocytes. J Physiol. 1996; 493: 793800.
43. Gupta RC, Neumann J, Watanabe AM, Sabbah HN. Inhibition of type 1 protein phosphatase activity by activation of beta-adrenoceptors in ventricular myocardium. Biochem Pharmacol. 2002; 63: 10691076.[CrossRef][Medline] [Order article via Infotrieve]
44. Palanivel R, Veluthakal R, Kowluru A. Regulation by glucose and calcium of the carboxylmethylation of the catalytic subunit of protein phosphatase 2A in insulin-secreting INS-1 cells. Am J Physiol. 2004; 286: E1032E1041.
45. Gergs U, Boknik P, Buchwalow I, Fabritz L, Matus M, Justus I, Hanske G, Schmitz W, Neumann J. Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function. J Biol Chem. 2004; 279: 4082740834.
| Footnotes |
|---|
This article has been cited by other articles:
![]() |
Y. Ikeda, M. Hoshijima, and K. R. Chien Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure Physiology, February 1, 2008; 23(1): 6 - 16. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |